Premium
Prospects of Cell Therapy for Disorders of Myelin
Author(s) -
BenHur Tamir,
Goldman Steven A.
Publication year - 2008
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1444.014
Subject(s) - remyelination , myelin , progenitor cell , demyelinating disorder , multiple sclerosis , transplantation , neuroscience , medicine , cell therapy , stem cell , disease , oligodendrocyte , central nervous system , bioinformatics , immunology , biology , pathology , microbiology and biotechnology
Recent advances in stem cell biology have raised expectations that both diseases of, and injuries to, the central nervous system may be ameliorated by cell transplantation. In particular, cell therapy has been studied for inducing efficient remyelination in disorders of myelin, including both the largely pediatric disorders of myelin formation and maintenance and the acquired demyelinations of both children and adults. Potential cell‐based treatments of two major groups of disorders include both delivery of myelinogenic replacements and mobilization of residual oligodendrocyte progenitor cells as a means of stimulating endogenous repair; the choice of modality is then predicated upon the disease target. In this review we consider the potential application of cell‐based therapeutic strategies to disorders of myelin, highlighting the promises as well as the problems and potential perils of this treatment approach.